Skip to main content
Top
Published in: Endocrine 2/2015

01-03-2015 | Endocrine Genetics/Epigenetics

Calcium-sensing receptor sequencing in 21 patients with idiopathic or familial parathyroid disorder: pitfalls and characterization of a novel I32 V loss-of-function mutation

Authors: Auryan Szalat, Michal Shahar, Shoshana Shpitzen, Boaz Nachmias, Gabriel Munter, David Gillis, Ronen Durst, Dror Mevorach, Eran Leitersdorf, Vardiella Meiner, Haim Rosen

Published in: Endocrine | Issue 2/2015

Login to get access

Abstract

The calcium-sensing receptor (CaSR) is a G-protein-coupled receptor with a crucial role in calcium homeostasis. Mutations in the CaSR gene may lead to specific parathyroid disorders due to either gain-of-function (autosomal dominant hypercalciuric hypocalcemia; ADHH) or loss-of-function (familial hypocalciuric hypercalcemia; FHH). Our aim was to evaluate CaSR mutations as a cause of disease in selected patients. We identified and recruited patients with phenotypes suggestive of CaSR-related parathyroid disorders. DNA was extracted, and CaSR gene was sequenced. Live-ratiometric measurements of intracellular [Ca2+] and Western blot assays for evaluation of MAPK phosphorylation in response to changes in extracellular [Ca2+] were performed in transiently transfected HEK-293T cells to functionally characterize mutants. A total of 21 patients were evaluated, seven of them with idiopathic hypoparathyroidism (suspected ADHH) and 14 with hyperparathyroidism (suspected FHH). In the latter group two patients were found to harbor missense mutations: a novel heterozygous I32 V mutation in a female index case and a sporadic known R185Q mutation in a 1-year-old girl. In-vitro functional studies showed that I32 V is an inactivating mutation. In our study, most patients had normal CaSR sequencing. This suggests that phenotypic pitfalls may occur at time of patients’ selection for CaSR sequencing. In one patient with strong positive pre-test probability based on both familial history and appropriate phenotype, a novel I32 V mutation leading to FHH was identified and characterized. In cases of familial parathyroid disorders, CaSR sequencing should be performed, but if negative, one should consider involvement of alternative genes or mechanisms.
Literature
1.
go back to reference N. Chattopadhyay, A. Mithal, E.M. Brown, The calcium-sensing receptor: a window into the physiology and pathophysiology of mineral ion metabolism. Endocr. Rev. 17(4), 289–307 (1996)PubMed N. Chattopadhyay, A. Mithal, E.M. Brown, The calcium-sensing receptor: a window into the physiology and pathophysiology of mineral ion metabolism. Endocr. Rev. 17(4), 289–307 (1996)PubMed
2.
go back to reference D. Riccardi, E.M. Brown, Physiology and pathophysiology of the calcium-sensing receptor in the kidney. Am. J. Physiol. Renal. Physiol. 298(3), F485–F499 (2009)CrossRefPubMedCentralPubMed D. Riccardi, E.M. Brown, Physiology and pathophysiology of the calcium-sensing receptor in the kidney. Am. J. Physiol. Renal. Physiol. 298(3), F485–F499 (2009)CrossRefPubMedCentralPubMed
3.
go back to reference A. Hofer, E. Brown, Extracellular calcium sensing and signalling. Nat. Rev. Mol. Cell Biol. 4(7), 530–538 (2003)CrossRefPubMed A. Hofer, E. Brown, Extracellular calcium sensing and signalling. Nat. Rev. Mol. Cell Biol. 4(7), 530–538 (2003)CrossRefPubMed
4.
go back to reference C. Ye, K. Rogers, M. Bai, S.J. Quinn, E.M. Brown, P.M. Vassilev, Agonists of the Ca(2+)-sensing receptor (CaR) activate nonselective cation channels in HEK293 cells stably transfected with the human CaR. Biochem. Biophys. Res. Commun. 226(2), 572–579 (1996)CrossRefPubMed C. Ye, K. Rogers, M. Bai, S.J. Quinn, E.M. Brown, P.M. Vassilev, Agonists of the Ca(2+)-sensing receptor (CaR) activate nonselective cation channels in HEK293 cells stably transfected with the human CaR. Biochem. Biophys. Res. Commun. 226(2), 572–579 (1996)CrossRefPubMed
5.
go back to reference A.L. Magno, B.K. Ward, T. Ratajczak, The calcium-sensing receptor: a molecular perspective. Endocr. Rev. 32(1), 3–30 (2011)CrossRefPubMed A.L. Magno, B.K. Ward, T. Ratajczak, The calcium-sensing receptor: a molecular perspective. Endocr. Rev. 32(1), 3–30 (2011)CrossRefPubMed
6.
go back to reference E. Brown, Clinical lessons from the calcium-sensing receptor. Nat. Clin. Pract. Endocrinol. Metab. 3(2), 122–133 (2007)CrossRefPubMed E. Brown, Clinical lessons from the calcium-sensing receptor. Nat. Clin. Pract. Endocrinol. Metab. 3(2), 122–133 (2007)CrossRefPubMed
7.
go back to reference M. Yamamoto, T. Akatsu, T. Nagase, E. Ogata, Comparison of hypocalcemic hypercalciuria between patients with idiopathic hypoparathyroidism and those with gain-of-function mutations in the calcium-sensing receptor: is it possible to differentiate the two disorders? J. Clin. Endocrinol. Metab. 85(12), 4583–4591 (2000)CrossRefPubMed M. Yamamoto, T. Akatsu, T. Nagase, E. Ogata, Comparison of hypocalcemic hypercalciuria between patients with idiopathic hypoparathyroidism and those with gain-of-function mutations in the calcium-sensing receptor: is it possible to differentiate the two disorders? J. Clin. Endocrinol. Metab. 85(12), 4583–4591 (2000)CrossRefPubMed
8.
go back to reference I.R. Gunn, D. Gaffney, Clinical and laboratory features of calcium-sensing receptor disorders: a systematic review. Ann. Clin. Biochem. 41(Pt 6), 441–458 (2004)CrossRefPubMed I.R. Gunn, D. Gaffney, Clinical and laboratory features of calcium-sensing receptor disorders: a systematic review. Ann. Clin. Biochem. 41(Pt 6), 441–458 (2004)CrossRefPubMed
9.
go back to reference O. Egbuna, E. Brown, Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations. Best Pract. Res. Clin. Rheumatol. 22(1), 129–148 (2008)CrossRefPubMedCentralPubMed O. Egbuna, E. Brown, Hypercalcaemic and hypocalcaemic conditions due to calcium-sensing receptor mutations. Best Pract. Res. Clin. Rheumatol. 22(1), 129–148 (2008)CrossRefPubMedCentralPubMed
10.
go back to reference J. Varghese, T. Rich, C. Jimenez, Benign familial hypocalciuric hypercalcemia. Endocr. Pract. 17(Suppl 1), 13–17 (2011)CrossRefPubMed J. Varghese, T. Rich, C. Jimenez, Benign familial hypocalciuric hypercalcemia. Endocr. Pract. 17(Suppl 1), 13–17 (2011)CrossRefPubMed
11.
go back to reference U. Quitterer, M. Hoffmann, M. Freichel, M.J. Lohse, Paradoxical block of parathormone secretion is mediated by increased activity of G alpha subunits. J. Biol. Chem. 276(9), 6763–6769 (2001)CrossRefPubMed U. Quitterer, M. Hoffmann, M. Freichel, M.J. Lohse, Paradoxical block of parathormone secretion is mediated by increased activity of G alpha subunits. J. Biol. Chem. 276(9), 6763–6769 (2001)CrossRefPubMed
12.
go back to reference S.H. Pearce, M. Bai, S.J. Quinn, O. Kifor, E.M. Brown, R.V. Thakker, Functional characterization of calcium-sensing receptor mutations expressed in human embryonic kidney cells. J. Clin. Investig. 98(8), 1860–1866 (1996)CrossRefPubMedCentralPubMed S.H. Pearce, M. Bai, S.J. Quinn, O. Kifor, E.M. Brown, R.V. Thakker, Functional characterization of calcium-sensing receptor mutations expressed in human embryonic kidney cells. J. Clin. Investig. 98(8), 1860–1866 (1996)CrossRefPubMedCentralPubMed
13.
go back to reference I.A. Adzhubei, S. Schmidt, L. Peshkin, V.E. Ramensky, A. Gerasimova, P. Bork, A.S. Kondrashov, S.R. Sunyaev, A method and server for predicting damaging missense mutations. Nat. Methods 7(4), 248–249 (2010)CrossRefPubMedCentralPubMed I.A. Adzhubei, S. Schmidt, L. Peshkin, V.E. Ramensky, A. Gerasimova, P. Bork, A.S. Kondrashov, S.R. Sunyaev, A method and server for predicting damaging missense mutations. Nat. Methods 7(4), 248–249 (2010)CrossRefPubMedCentralPubMed
14.
go back to reference J.M. Schwarz, C. Rodelsperger, M. Schuelke, D. Seelow, Mutationtaster evaluates disease-causing potential of sequence alterations. Nat. Methods 7(8), 575–576 (2010)CrossRefPubMed J.M. Schwarz, C. Rodelsperger, M. Schuelke, D. Seelow, Mutationtaster evaluates disease-causing potential of sequence alterations. Nat. Methods 7(8), 575–576 (2010)CrossRefPubMed
15.
go back to reference M. Bai, S. Trivedi, E.M. Brown, Dimerization of the extracellular calcium-sensing receptor (CaR) on the cell surface of CaR-transfected HEK293 cells. J. Biol. Chem. 273(36), 23605–23610 (1998)CrossRefPubMed M. Bai, S. Trivedi, E.M. Brown, Dimerization of the extracellular calcium-sensing receptor (CaR) on the cell surface of CaR-transfected HEK293 cells. J. Biol. Chem. 273(36), 23605–23610 (1998)CrossRefPubMed
16.
go back to reference M.R. Pollak, E.M. Brown, Y.H. Chou, S.C. Hebert, S.J. Marx, B. Steinmann, T. Levi, C.E. Seidman, J.G. Seidman, Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75(7), 1297–1303 (1993)CrossRefPubMed M.R. Pollak, E.M. Brown, Y.H. Chou, S.C. Hebert, S.J. Marx, B. Steinmann, T. Levi, C.E. Seidman, J.G. Seidman, Mutations in the human Ca(2+)-sensing receptor gene cause familial hypocalciuric hypercalcemia and neonatal severe hyperparathyroidism. Cell 75(7), 1297–1303 (1993)CrossRefPubMed
17.
go back to reference H. Heath 3rd, S. Odelberg, C.E. Jackson, B.T. Teh, N. Hayward, C. Larsson, N.R. Buist, K.J. Krapcho, B.C. Hung, I.V. Capuano, J.E. Garrett, M.F. Leppert, Clustered inactivating mutations and benign polymorphisms of the calcium receptor gene in familial benign hypocalciuric hypercalcemia suggest receptor functional domains. J. Clin. Endocrinol. Metab. 81(4), 1312–1317 (1996)CrossRefPubMed H. Heath 3rd, S. Odelberg, C.E. Jackson, B.T. Teh, N. Hayward, C. Larsson, N.R. Buist, K.J. Krapcho, B.C. Hung, I.V. Capuano, J.E. Garrett, M.F. Leppert, Clustered inactivating mutations and benign polymorphisms of the calcium receptor gene in familial benign hypocalciuric hypercalcemia suggest receptor functional domains. J. Clin. Endocrinol. Metab. 81(4), 1312–1317 (1996)CrossRefPubMed
18.
go back to reference B. Obermannova, K. Banghova, Z. Sumnik, H.M. Dvorakova, J. Betka, F. Fencl, S. Kolouskova, O. Cinek, J. Lebl, Unusually severe phenotype of neonatal primary hyperparathyroidism due to a heterozygous inactivating mutation in the CASR gene. Eur. J. Pediatr. 168(5), 569–573 (2009)CrossRefPubMed B. Obermannova, K. Banghova, Z. Sumnik, H.M. Dvorakova, J. Betka, F. Fencl, S. Kolouskova, O. Cinek, J. Lebl, Unusually severe phenotype of neonatal primary hyperparathyroidism due to a heterozygous inactivating mutation in the CASR gene. Eur. J. Pediatr. 168(5), 569–573 (2009)CrossRefPubMed
19.
go back to reference C.M. Reh, G.N. Hendy, D.E. Cole, D.D. Jeandron, Neonatal hyperparathyroidism with a heterozygous calcium-sensing receptor (CASR) R185Q mutation: clinical benefit from cinacalcet. J. Clin. Endocrinol. Metab. 96(4), E707–E712 (2011)CrossRefPubMed C.M. Reh, G.N. Hendy, D.E. Cole, D.D. Jeandron, Neonatal hyperparathyroidism with a heterozygous calcium-sensing receptor (CASR) R185Q mutation: clinical benefit from cinacalcet. J. Clin. Endocrinol. Metab. 96(4), E707–E712 (2011)CrossRefPubMed
20.
go back to reference M. Bai, S.H. Pearce, O. Kifor, S. Trivedi, U.G. Stauffer, R.V. Thakker, E.M. Brown, B. Steinmann, In vivo and in vitro characterization of neonatal hyperparathyroidism resulting from a de novo, heterozygous mutation in the Ca2+-sensing receptor gene: normal maternal calcium homeostasis as a cause of secondary hyperparathyroidism in familial benign hypocalciuric hypercalcemia. J. Clin. Investig. 99(1), 88–96 (1997)CrossRefPubMedCentralPubMed M. Bai, S.H. Pearce, O. Kifor, S. Trivedi, U.G. Stauffer, R.V. Thakker, E.M. Brown, B. Steinmann, In vivo and in vitro characterization of neonatal hyperparathyroidism resulting from a de novo, heterozygous mutation in the Ca2+-sensing receptor gene: normal maternal calcium homeostasis as a cause of secondary hyperparathyroidism in familial benign hypocalciuric hypercalcemia. J. Clin. Investig. 99(1), 88–96 (1997)CrossRefPubMedCentralPubMed
21.
go back to reference S.E. Christensen, P.H. Nissen, P. Vestergaard, L. Heickendorff, K. Brixen, L. Mosekilde, Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods. Clin. Endocrinol. (Oxf) 69(5), 713–720 (2008)CrossRef S.E. Christensen, P.H. Nissen, P. Vestergaard, L. Heickendorff, K. Brixen, L. Mosekilde, Discriminative power of three indices of renal calcium excretion for the distinction between familial hypocalciuric hypercalcaemia and primary hyperparathyroidism: a follow-up study on methods. Clin. Endocrinol. (Oxf) 69(5), 713–720 (2008)CrossRef
22.
go back to reference Y.H. Chou, M.R. Pollak, M.L. Brandi, G. Toss, H. Arnqvist, A.B. Atkinson, S.E. Papapoulos, S. Marx, E.M. Brown, J.G. Seidman et al., Mutations in the human Ca(2+)-sensing-receptor gene that cause familial hypocalciuric hypercalcemia. Am. J. Hum. Genet. 56(5), 1075–1079 (1995)PubMedCentralPubMed Y.H. Chou, M.R. Pollak, M.L. Brandi, G. Toss, H. Arnqvist, A.B. Atkinson, S.E. Papapoulos, S. Marx, E.M. Brown, J.G. Seidman et al., Mutations in the human Ca(2+)-sensing-receptor gene that cause familial hypocalciuric hypercalcemia. Am. J. Hum. Genet. 56(5), 1075–1079 (1995)PubMedCentralPubMed
23.
go back to reference V. Guarnieri, L. Canaff, F.H. Yun, A. Scillitani, C. Battista, L.A. Muscarella, B.Y. Wong, A. Notarangelo, L. D’Agruma, M. Sacco, D.E. Cole, G.N. Hendy, Calcium-sensing receptor (CASR) mutations in hypercalcemic states: studies from a single endocrine clinic over three years. J. Clin. Endocrinol. Metab. 95(4), 1819–1829 (2010)CrossRefPubMed V. Guarnieri, L. Canaff, F.H. Yun, A. Scillitani, C. Battista, L.A. Muscarella, B.Y. Wong, A. Notarangelo, L. D’Agruma, M. Sacco, D.E. Cole, G.N. Hendy, Calcium-sensing receptor (CASR) mutations in hypercalcemic states: studies from a single endocrine clinic over three years. J. Clin. Endocrinol. Metab. 95(4), 1819–1829 (2010)CrossRefPubMed
24.
go back to reference S.H. Pearce, D. Trump, C. Wooding, G.M. Besser, S.L. Chew, D.B. Grant, D.A. Heath, I.A. Hughes, C.R. Paterson, M.P. Whyte et al., Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. J. Clin. Investig. 96(6), 2683–2692 (1995)CrossRefPubMedCentralPubMed S.H. Pearce, D. Trump, C. Wooding, G.M. Besser, S.L. Chew, D.B. Grant, D.A. Heath, I.A. Hughes, C.R. Paterson, M.P. Whyte et al., Calcium-sensing receptor mutations in familial benign hypercalcemia and neonatal hyperparathyroidism. J. Clin. Investig. 96(6), 2683–2692 (1995)CrossRefPubMedCentralPubMed
25.
go back to reference K. Frank-Raue, G. Leidig-Bruckner, C. Haag, E. Schulze, A. Lorenz, H. Schmitz-Winnenthal, F. Raue, Inactivating calcium-sensing receptor mutations in patients with primary hyperparathyroidism. Clin. Endocrinol. (Oxf) 75(1), 50–55 (2011)CrossRef K. Frank-Raue, G. Leidig-Bruckner, C. Haag, E. Schulze, A. Lorenz, H. Schmitz-Winnenthal, F. Raue, Inactivating calcium-sensing receptor mutations in patients with primary hyperparathyroidism. Clin. Endocrinol. (Oxf) 75(1), 50–55 (2011)CrossRef
26.
go back to reference F. Raue, J. Pichl, H.G. Dorr, D. Schnabel, P. Heidemann, G. Hammersen, C. Jaursch-Hancke, R. Santen, C. Schofl, M. Wabitsch, C. Haag, E. Schulze, K. Frank-Raue, Activating mutations in the calcium-sensing receptor: genetic and clinical spectrum in 25 patients with autosomal dominant hypocalcaemia-a German survey. Clin. Endocrinol. (Oxf) 75(6), 760–765 (2011)CrossRef F. Raue, J. Pichl, H.G. Dorr, D. Schnabel, P. Heidemann, G. Hammersen, C. Jaursch-Hancke, R. Santen, C. Schofl, M. Wabitsch, C. Haag, E. Schulze, K. Frank-Raue, Activating mutations in the calcium-sensing receptor: genetic and clinical spectrum in 25 patients with autosomal dominant hypocalcaemia-a German survey. Clin. Endocrinol. (Oxf) 75(6), 760–765 (2011)CrossRef
27.
go back to reference R. Sarin, N. Tomar, D. Ray, N. Gupta, Y.D. Sharma, R. Goswami, Absence of pathogenic calcium sensing receptor mutations in sporadic idiopathic hypoparathyroidism. Clin. Endocrinol. (Oxf) 65(3), 359–363 (2006)CrossRef R. Sarin, N. Tomar, D. Ray, N. Gupta, Y.D. Sharma, R. Goswami, Absence of pathogenic calcium sensing receptor mutations in sporadic idiopathic hypoparathyroidism. Clin. Endocrinol. (Oxf) 65(3), 359–363 (2006)CrossRef
28.
go back to reference A. Lienhardt, M. Bai, J. Lagarde, M. Rigaud, Z. Zhang, Y. Jiang, M. Kottler, E. Brown, M. Garabédian, Activating mutations of the calcium-sensing receptor: management of hypocalcemia. J. Clin. Endocrinol. Metab. 86(11), 5313–5323 (2001)CrossRefPubMed A. Lienhardt, M. Bai, J. Lagarde, M. Rigaud, Z. Zhang, Y. Jiang, M. Kottler, E. Brown, M. Garabédian, Activating mutations of the calcium-sensing receptor: management of hypocalcemia. J. Clin. Endocrinol. Metab. 86(11), 5313–5323 (2001)CrossRefPubMed
29.
go back to reference R. Eastell, A. Arnold, M.L. Brandi, E.M. Brown, P. D’Amour, D.A. Hanley, D.S. Rao, M.R. Rubin, D. Goltzman, S.J. Silverberg, S.J. Marx, M. Peacock, L. Mosekilde, R. Bouillon, E.M. Lewiecki, Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab. 94(2), 340–350 (2009)CrossRefPubMed R. Eastell, A. Arnold, M.L. Brandi, E.M. Brown, P. D’Amour, D.A. Hanley, D.S. Rao, M.R. Rubin, D. Goltzman, S.J. Silverberg, S.J. Marx, M. Peacock, L. Mosekilde, R. Bouillon, E.M. Lewiecki, Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the third international workshop. J. Clin. Endocrinol. Metab. 94(2), 340–350 (2009)CrossRefPubMed
30.
go back to reference K. Sato, Y. Hasegawa, J. Nakae, K. Nanao, I. Takahashi, T. Tajima, N. Shinohara, K. Fujieda, Hydrochlorothiazide effectively reduces urinary calcium excretion in two Japanese patients with gain-of-function mutations of the calcium-sensing receptor gene. J. Clin. Endocrinol. Metab. 87(7), 3068–3073 (2002)CrossRefPubMed K. Sato, Y. Hasegawa, J. Nakae, K. Nanao, I. Takahashi, T. Tajima, N. Shinohara, K. Fujieda, Hydrochlorothiazide effectively reduces urinary calcium excretion in two Japanese patients with gain-of-function mutations of the calcium-sensing receptor gene. J. Clin. Endocrinol. Metab. 87(7), 3068–3073 (2002)CrossRefPubMed
31.
go back to reference A. Szalat, H. Mazeh, H.R. Freund, Lithium-associated hyperparathyroidism: report of four cases and review of the literature. Eur. J. Endocrinol. 160(2), 317–323 (2009)CrossRefPubMed A. Szalat, H. Mazeh, H.R. Freund, Lithium-associated hyperparathyroidism: report of four cases and review of the literature. Eur. J. Endocrinol. 160(2), 317–323 (2009)CrossRefPubMed
32.
go back to reference M.A. Nesbit, F.M. Hannan, S.A. Howles, V.N. Babinsky, R.A. Head, T. Cranston, N. Rust, M.R. Hobbs, H. Heath 3rd, R.V. Thakker, Mutations affecting G-protein subunit alpha11 in hypercalcemia and hypocalcemia. N. Engl. J. Med. 368(26), 2476–2486 (2013)CrossRefPubMedCentralPubMed M.A. Nesbit, F.M. Hannan, S.A. Howles, V.N. Babinsky, R.A. Head, T. Cranston, N. Rust, M.R. Hobbs, H. Heath 3rd, R.V. Thakker, Mutations affecting G-protein subunit alpha11 in hypercalcemia and hypocalcemia. N. Engl. J. Med. 368(26), 2476–2486 (2013)CrossRefPubMedCentralPubMed
33.
go back to reference M.A. Nesbit, F.M. Hannan, S.A. Howles, A.A. Reed, T. Cranston, C.E. Thakker, L. Gregory, A.J. Rimmer, N. Rust, U. Graham, P.J. Morrison, S.J. Hunter, M.P. Whyte, G. McVean, D. Buck, R.V. Thakker, Mutations in AP2S1 cause familial hypocalciuric hypercalcemia type 3. Nat. Genet. 45(1), 93–97 (2013)CrossRefPubMedCentralPubMed M.A. Nesbit, F.M. Hannan, S.A. Howles, A.A. Reed, T. Cranston, C.E. Thakker, L. Gregory, A.J. Rimmer, N. Rust, U. Graham, P.J. Morrison, S.J. Hunter, M.P. Whyte, G. McVean, D. Buck, R.V. Thakker, Mutations in AP2S1 cause familial hypocalciuric hypercalcemia type 3. Nat. Genet. 45(1), 93–97 (2013)CrossRefPubMedCentralPubMed
34.
go back to reference J.P. Bilezikian, A. Khan, J.T. Potts Jr, M.L. Brandi, B.L. Clarke, D. Shoback, H. Juppner, P. D’Amour, J. Fox, L. Rejnmark, L. Mosekilde, M.R. Rubin, D. Dempster, R. Gafni, M.T. Collins, J. Sliney, J. Sanders, Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J. Bone Miner. Res. 26(10), 2317–2337 (2011)CrossRefPubMedCentralPubMed J.P. Bilezikian, A. Khan, J.T. Potts Jr, M.L. Brandi, B.L. Clarke, D. Shoback, H. Juppner, P. D’Amour, J. Fox, L. Rejnmark, L. Mosekilde, M.R. Rubin, D. Dempster, R. Gafni, M.T. Collins, J. Sliney, J. Sanders, Hypoparathyroidism in the adult: epidemiology, diagnosis, pathophysiology, target-organ involvement, treatment, and challenges for future research. J. Bone Miner. Res. 26(10), 2317–2337 (2011)CrossRefPubMedCentralPubMed
35.
go back to reference R. Goswami, E. Brown, N. Kochupillai, N. Gupta, R. Rani, O. Kifor, N. Chattopadhyay, Prevalence of calcium sensing receptor autoantibodies in patients with sporadic idiopathic hypoparathyroidism. Eur. J. Endocrinol. 150(1), 9–18 (2004)CrossRefPubMed R. Goswami, E. Brown, N. Kochupillai, N. Gupta, R. Rani, O. Kifor, N. Chattopadhyay, Prevalence of calcium sensing receptor autoantibodies in patients with sporadic idiopathic hypoparathyroidism. Eur. J. Endocrinol. 150(1), 9–18 (2004)CrossRefPubMed
36.
go back to reference A. Mayer, C. Ploix, J. Orgiazzi, A. Desbos, A. Moreira, H. Vidal, J.C. Monier, J. Bienvenu, N. Fabien, Calcium-sensing receptor autoantibodies are relevant markers of acquired hypoparathyroidism. J. Clin. Endocrinol. Metab. 89(9), 4484–4488 (2004)CrossRefPubMed A. Mayer, C. Ploix, J. Orgiazzi, A. Desbos, A. Moreira, H. Vidal, J.C. Monier, J. Bienvenu, N. Fabien, Calcium-sensing receptor autoantibodies are relevant markers of acquired hypoparathyroidism. J. Clin. Endocrinol. Metab. 89(9), 4484–4488 (2004)CrossRefPubMed
37.
go back to reference N. Gavalas, E. Kemp, K. Krohn, E. Brown, P. Watson, A. Weetman, The calcium-sensing receptor is a target of autoantibodies in patients with autoimmune polyendocrine syndrome type 1. J. Clin. Endocrinol. Metab. 92(6), 2107–2114 (2007)CrossRefPubMed N. Gavalas, E. Kemp, K. Krohn, E. Brown, P. Watson, A. Weetman, The calcium-sensing receptor is a target of autoantibodies in patients with autoimmune polyendocrine syndrome type 1. J. Clin. Endocrinol. Metab. 92(6), 2107–2114 (2007)CrossRefPubMed
38.
go back to reference O. Kifor, F.D. Moore Jr, M. Delaney, J. Garber, G.N. Hendy, R. Butters, P. Gao, T.L. Cantor, I. Kifor, E.M. Brown, J. Wysolmerski, A syndrome of hypocalciuric hypercalcemia caused by autoantibodies directed at the calcium-sensing receptor. J. Clin. Endocrinol. Metab. 88(1), 60–72 (2003)CrossRefPubMed O. Kifor, F.D. Moore Jr, M. Delaney, J. Garber, G.N. Hendy, R. Butters, P. Gao, T.L. Cantor, I. Kifor, E.M. Brown, J. Wysolmerski, A syndrome of hypocalciuric hypercalcemia caused by autoantibodies directed at the calcium-sensing receptor. J. Clin. Endocrinol. Metab. 88(1), 60–72 (2003)CrossRefPubMed
39.
go back to reference J. Pallais, O. Kifor, Y. Chen, D. Slovik, E. Brown, Acquired hypocalciuric hypercalcemia due to autoantibodies against the calcium-sensing receptor. N. Engl. J. Med. 351(4), 362–369 (2004)CrossRefPubMed J. Pallais, O. Kifor, Y. Chen, D. Slovik, E. Brown, Acquired hypocalciuric hypercalcemia due to autoantibodies against the calcium-sensing receptor. N. Engl. J. Med. 351(4), 362–369 (2004)CrossRefPubMed
40.
go back to reference J.C. Pallais, E.H. Kemp, C. Bergwitz, L. Kantham, D.M. Slovik, A.P. Weetman, E.M. Brown, Autoimmune hypocalciuric hypercalcemia unresponsive to glucocorticoid therapy in a patient with blocking autoantibodies against the calcium-sensing receptor. J. Clin. Endocrinol. Metab. 96(3), 672–680 (2010)CrossRefPubMedCentralPubMed J.C. Pallais, E.H. Kemp, C. Bergwitz, L. Kantham, D.M. Slovik, A.P. Weetman, E.M. Brown, Autoimmune hypocalciuric hypercalcemia unresponsive to glucocorticoid therapy in a patient with blocking autoantibodies against the calcium-sensing receptor. J. Clin. Endocrinol. Metab. 96(3), 672–680 (2010)CrossRefPubMedCentralPubMed
41.
go back to reference M. Alimohammadi, P. Björklund, A. Hallgren, N. Pöntynen, G. Szinnai, N. Shikama, M.P. Keller, O. Ekwall, S.A. Kinkel, E.S. Husebye, J. Gustafsson, F. Rorsman, L. Peltonen, C. Betterle, J. Perheentupa, G. Akerström, G. Westin, H.S. Scott, G.A. Holländer, O. Kämpe, Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen. N. Eng. J. Med. 358(10), 1018–1028 (2008)CrossRef M. Alimohammadi, P. Björklund, A. Hallgren, N. Pöntynen, G. Szinnai, N. Shikama, M.P. Keller, O. Ekwall, S.A. Kinkel, E.S. Husebye, J. Gustafsson, F. Rorsman, L. Peltonen, C. Betterle, J. Perheentupa, G. Akerström, G. Westin, H.S. Scott, G.A. Holländer, O. Kämpe, Autoimmune polyendocrine syndrome type 1 and NALP5, a parathyroid autoantigen. N. Eng. J. Med. 358(10), 1018–1028 (2008)CrossRef
42.
go back to reference N. Tomar, E. Kaushal, M. Das, N. Gupta, C. Betterle, R. Goswami, Prevalence and significance of NALP5 autoantibodies in patients with idiopathic hypoparathyroidism. J. Clin. Endocrinol. Metab. 97(4), 1219–1226 (2012)CrossRefPubMed N. Tomar, E. Kaushal, M. Das, N. Gupta, C. Betterle, R. Goswami, Prevalence and significance of NALP5 autoantibodies in patients with idiopathic hypoparathyroidism. J. Clin. Endocrinol. Metab. 97(4), 1219–1226 (2012)CrossRefPubMed
Metadata
Title
Calcium-sensing receptor sequencing in 21 patients with idiopathic or familial parathyroid disorder: pitfalls and characterization of a novel I32 V loss-of-function mutation
Authors
Auryan Szalat
Michal Shahar
Shoshana Shpitzen
Boaz Nachmias
Gabriel Munter
David Gillis
Ronen Durst
Dror Mevorach
Eran Leitersdorf
Vardiella Meiner
Haim Rosen
Publication date
01-03-2015
Publisher
Springer US
Published in
Endocrine / Issue 2/2015
Print ISSN: 1355-008X
Electronic ISSN: 1559-0100
DOI
https://doi.org/10.1007/s12020-014-0370-3

Other articles of this Issue 2/2015

Endocrine 2/2015 Go to the issue